114 related articles for article (PubMed ID: 27795507)
1. [Progress in the treatment of mature T-cell lymphoma].
Suzuki R
Rinsho Ketsueki; 2016; 57(10):2000-2007. PubMed ID: 27795507
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic transplantation in T-cell lymphomas.
Schmitz N; Wu HS; Glass B
Semin Hematol; 2014 Jan; 51(1):67-72. PubMed ID: 24468318
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.
Sonnen R; Schmidt WP; Müller-Hermelink HK; Schmitz N
Br J Haematol; 2005 May; 129(3):366-72. PubMed ID: 15842660
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).
Dearden CE; Johnson R; Pettengell R; Devereux S; Cwynarski K; Whittaker S; McMillan A;
Br J Haematol; 2011 May; 153(4):451-85. PubMed ID: 21480860
[TBL] [Abstract][Full Text] [Related]
6. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
7. Treatment algorithms for mature T-cell and natural killer-cell neoplasms.
Tse E; Kwong YL
Future Oncol; 2011 Sep; 7(9):1101-12. PubMed ID: 21919697
[TBL] [Abstract][Full Text] [Related]
8. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
[TBL] [Abstract][Full Text] [Related]
10. Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
Iqbal J; Wilcox R; Naushad H; Rohr J; Heavican TB; Wang C; Bouska A; Fu K; Chan WC; Vose JM
Blood Rev; 2016 Mar; 30(2):89-100. PubMed ID: 26319391
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
12. [Peripheral T-cell lymphoma: diagnosis and treatment].
Reimer P; Hentrich M
Dtsch Med Wochenschr; 2006 Mar; 131(13):685-90. PubMed ID: 16555177
[TBL] [Abstract][Full Text] [Related]
13. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
[TBL] [Abstract][Full Text] [Related]
15. Novel therapeutic agents for T-cell lymphomas.
Chan TS; Kwong YL; Tse E
Discov Med; 2013 Aug; 16(86):27-35. PubMed ID: 23911229
[TBL] [Abstract][Full Text] [Related]
16. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.
Armitage JO; Hsi ED; Foss FM
Clin Adv Hematol Oncol; 2010 Dec; 8(12 Suppl 22):1-15. PubMed ID: 21491667
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
19. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
